From the Chair
From the Chair
Advertisement
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | July 7, 2025
Editorial board chair Dr. Ajay Singh discusses how GFR may vary between sexes and affect rates of CKD.
Read More
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | May 9, 2025
Ajay Singh talks dialytrauma—harmful effects of dialysis in patients with AKI moving from inpatient to outpatient care.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | June 13, 2025
Ajay Singh discusses the state of rare kidney disease research.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | June 13, 2025
Dr. Ajay Singh and others pay tribute to Dr. Barry Brenner, a leading nephrologist who passed away in August 2024.
Ajay K. Singh, MBBS, FRCP, MBANephrology Times | June 13, 2025
Dr. Ajay Singh discusses the reasons why medical students and residents are not choosing to pursue careers in nephrology.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | June 13, 2025
Ajay Singh pays tribute to the late nephrologist and researcher Nicolaos Madias, MD, of Tufts Medical Center.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | June 23, 2025
The four-pillar approach to treating diabetic kidney disease (DKD) has been endorsed by high-quality trials, such as FLOW. 
Ajay K. Singh, MBBS, FRCP, MBAIgA Nephropathy | June 13, 2025
IgA nephropathy (IgAN) is on the cusp of a transformational change in its treatment.
Ajay K. Singh, MBBS, FRCP, MBAIgA Nephropathy | August 23, 2024
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 23, 2024
The benefit-risk ratio and considerations about unmet need are worth considering.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 23, 2024
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 23, 2024
The first part of the dialysis moonshot is to prevent the need for dialysis.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 23, 2024
Measuring eGFR and UACR is a key component of guideline-directed medical therapy for patients with CKD from type 2 diabetes.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | February 5, 2024
The most important patients who should receive treatment with SGLT2 inhibitors are those with CKD and type 2 diabetes.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 23, 2024
Sodium-glucose transport protein 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, block SGLT2 cotransporters in the ...
Ajay K. Singh, MBBS, FRCP, MBAChronic Kidney Disease | February 5, 2024
From the Chair ...
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | February 5, 2024
From the Chair ...
Advertisement
Advertisement
Latest News

July 16, 2025